Expert Insights

Tycel Phillips, MD, reviews standard therapies utilized for patients with MCL, including nonaggressive regimens and BTK inhibitor therapies.

Sarah Rutherford, MD, debates why she believes CAR-T therapy is the preferred treatment for patients with early progressing FL after 2 lines of prior therapy.

Preetesh Jain, MD, discusses results from a phase 2 trial exploring the efficacy and safety of ibrutinib plus rituximab for the first-line treatment of older patients with MCL.

Andrew Zelenetz, MD, PhD, discusses results from a phase 2 trial assessing triplet therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated CLL or SLL and exploring MRD as a biomarker for treatment duration.

Welela Tereffe, MD, MPH, highlights MD Anderson Cancer Center’s impact on the future of cancer care and immunotherapy research, as the center celebrates its 80th anniversary.

Tanya Siddiqi, MD, shares results and insights of the TRANSCEND CLL 004 study of lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy for patients with CLL.

Lavanya Lokhande, PhD, discusses results from a study, presented at the AACR Annual Meeting, which investigated T-cell subpopulations profiled by spatial proteome among patients with MCL.

Gaël Roué, PhD, highlights a study providing insight into how the loss of the small GTPase RhoA enhances lymphomagenesis and impairs the activity of lenalidomide in patients with MCL.